Transplantation of bone marrow-derived stem cells: A promising therapy for stroke

Yamei Tang, Takao Yasuhara, Koichi Hara, Noriyuki Matsukawa, Mina Maki, Guolong Yu, Lin Xu, David C. Hess, Cesario V. Borlongan

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Stroke remains a major cause of death in the US and around the world. Over the last decade, stem cell therapy has been introduced as an experimental treatment for stroke. Transplantation of stem cells or progenitors into the injured site to replace the nonfunctional cells, and enhancement of proliferation or differentiation of endogenous stem or progenitor cells stand as the two major cell-based strategies. Potential sources of stem/progenitor cells for stroke include fetal neural stem cells, embryonic stem cells, neuroteratocarcinoma cells, umbilical cord blood-derived nonhematopoietic stem cells, and bone marrow-derived stem cells. The goal of this article is to provide an update on the preclinical use of bone marrow-derived stem cells with major emphasis on mesenchymal stem cells (MSCs) and multipotent adult progenitor cells (MAPCs) because they are currently most widely applied in experimental stroke studies and are now being phased into early clinical trials. The phenotypic features of MSCs and MAPCs, as well as their application in stroke, are described.

Original languageEnglish (US)
Pages (from-to)159-169
Number of pages11
JournalCell Transplantation
Volume16
Issue number2
StatePublished - May 4 2007

Fingerprint

Stem cells
Bone Marrow Transplantation
Bone
Stem Cells
Stroke
Therapeutics
Mesenchymal Stromal Cells
Fetal Stem Cells
Bone Marrow
Neural Stem Cells
Stem Cell Transplantation
Embryonic Stem Cells
Cell- and Tissue-Based Therapy
Fetal Blood
Cell Differentiation
Cause of Death
Blood
Cell Proliferation
Clinical Trials

Keywords

  • Neural repair
  • Neurological disorder
  • Neurotrophic factor
  • Progenitor cell

ASJC Scopus subject areas

  • Biomedical Engineering
  • Cell Biology
  • Transplantation

Cite this

Tang, Y., Yasuhara, T., Hara, K., Matsukawa, N., Maki, M., Yu, G., ... Borlongan, C. V. (2007). Transplantation of bone marrow-derived stem cells: A promising therapy for stroke. Cell Transplantation, 16(2), 159-169.

Transplantation of bone marrow-derived stem cells : A promising therapy for stroke. / Tang, Yamei; Yasuhara, Takao; Hara, Koichi; Matsukawa, Noriyuki; Maki, Mina; Yu, Guolong; Xu, Lin; Hess, David C.; Borlongan, Cesario V.

In: Cell Transplantation, Vol. 16, No. 2, 04.05.2007, p. 159-169.

Research output: Contribution to journalArticle

Tang, Y, Yasuhara, T, Hara, K, Matsukawa, N, Maki, M, Yu, G, Xu, L, Hess, DC & Borlongan, CV 2007, 'Transplantation of bone marrow-derived stem cells: A promising therapy for stroke', Cell Transplantation, vol. 16, no. 2, pp. 159-169.
Tang Y, Yasuhara T, Hara K, Matsukawa N, Maki M, Yu G et al. Transplantation of bone marrow-derived stem cells: A promising therapy for stroke. Cell Transplantation. 2007 May 4;16(2):159-169.
Tang, Yamei ; Yasuhara, Takao ; Hara, Koichi ; Matsukawa, Noriyuki ; Maki, Mina ; Yu, Guolong ; Xu, Lin ; Hess, David C. ; Borlongan, Cesario V. / Transplantation of bone marrow-derived stem cells : A promising therapy for stroke. In: Cell Transplantation. 2007 ; Vol. 16, No. 2. pp. 159-169.
@article{e897dc6c9267462b9f0b05324dd479c3,
title = "Transplantation of bone marrow-derived stem cells: A promising therapy for stroke",
abstract = "Stroke remains a major cause of death in the US and around the world. Over the last decade, stem cell therapy has been introduced as an experimental treatment for stroke. Transplantation of stem cells or progenitors into the injured site to replace the nonfunctional cells, and enhancement of proliferation or differentiation of endogenous stem or progenitor cells stand as the two major cell-based strategies. Potential sources of stem/progenitor cells for stroke include fetal neural stem cells, embryonic stem cells, neuroteratocarcinoma cells, umbilical cord blood-derived nonhematopoietic stem cells, and bone marrow-derived stem cells. The goal of this article is to provide an update on the preclinical use of bone marrow-derived stem cells with major emphasis on mesenchymal stem cells (MSCs) and multipotent adult progenitor cells (MAPCs) because they are currently most widely applied in experimental stroke studies and are now being phased into early clinical trials. The phenotypic features of MSCs and MAPCs, as well as their application in stroke, are described.",
keywords = "Neural repair, Neurological disorder, Neurotrophic factor, Progenitor cell",
author = "Yamei Tang and Takao Yasuhara and Koichi Hara and Noriyuki Matsukawa and Mina Maki and Guolong Yu and Lin Xu and Hess, {David C.} and Borlongan, {Cesario V.}",
year = "2007",
month = "5",
day = "4",
language = "English (US)",
volume = "16",
pages = "159--169",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "2",

}

TY - JOUR

T1 - Transplantation of bone marrow-derived stem cells

T2 - A promising therapy for stroke

AU - Tang, Yamei

AU - Yasuhara, Takao

AU - Hara, Koichi

AU - Matsukawa, Noriyuki

AU - Maki, Mina

AU - Yu, Guolong

AU - Xu, Lin

AU - Hess, David C.

AU - Borlongan, Cesario V.

PY - 2007/5/4

Y1 - 2007/5/4

N2 - Stroke remains a major cause of death in the US and around the world. Over the last decade, stem cell therapy has been introduced as an experimental treatment for stroke. Transplantation of stem cells or progenitors into the injured site to replace the nonfunctional cells, and enhancement of proliferation or differentiation of endogenous stem or progenitor cells stand as the two major cell-based strategies. Potential sources of stem/progenitor cells for stroke include fetal neural stem cells, embryonic stem cells, neuroteratocarcinoma cells, umbilical cord blood-derived nonhematopoietic stem cells, and bone marrow-derived stem cells. The goal of this article is to provide an update on the preclinical use of bone marrow-derived stem cells with major emphasis on mesenchymal stem cells (MSCs) and multipotent adult progenitor cells (MAPCs) because they are currently most widely applied in experimental stroke studies and are now being phased into early clinical trials. The phenotypic features of MSCs and MAPCs, as well as their application in stroke, are described.

AB - Stroke remains a major cause of death in the US and around the world. Over the last decade, stem cell therapy has been introduced as an experimental treatment for stroke. Transplantation of stem cells or progenitors into the injured site to replace the nonfunctional cells, and enhancement of proliferation or differentiation of endogenous stem or progenitor cells stand as the two major cell-based strategies. Potential sources of stem/progenitor cells for stroke include fetal neural stem cells, embryonic stem cells, neuroteratocarcinoma cells, umbilical cord blood-derived nonhematopoietic stem cells, and bone marrow-derived stem cells. The goal of this article is to provide an update on the preclinical use of bone marrow-derived stem cells with major emphasis on mesenchymal stem cells (MSCs) and multipotent adult progenitor cells (MAPCs) because they are currently most widely applied in experimental stroke studies and are now being phased into early clinical trials. The phenotypic features of MSCs and MAPCs, as well as their application in stroke, are described.

KW - Neural repair

KW - Neurological disorder

KW - Neurotrophic factor

KW - Progenitor cell

UR - http://www.scopus.com/inward/record.url?scp=34247632230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247632230&partnerID=8YFLogxK

M3 - Article

C2 - 17474297

AN - SCOPUS:34247632230

VL - 16

SP - 159

EP - 169

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 2

ER -